Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8260303rdf:typepubmed:Citationlld:pubmed
pubmed-article:8260303lifeskim:mentionsumls-concept:C2598156lld:lifeskim
pubmed-article:8260303lifeskim:mentionsumls-concept:C0684336lld:lifeskim
pubmed-article:8260303lifeskim:mentionsumls-concept:C1280551lld:lifeskim
pubmed-article:8260303lifeskim:mentionsumls-concept:C0243192lld:lifeskim
pubmed-article:8260303lifeskim:mentionsumls-concept:C0006400lld:lifeskim
pubmed-article:8260303lifeskim:mentionsumls-concept:C0032824lld:lifeskim
pubmed-article:8260303lifeskim:mentionsumls-concept:C0178602lld:lifeskim
pubmed-article:8260303lifeskim:mentionsumls-concept:C1555029lld:lifeskim
pubmed-article:8260303lifeskim:mentionsumls-concept:C0205263lld:lifeskim
pubmed-article:8260303lifeskim:mentionsumls-concept:C0917866lld:lifeskim
pubmed-article:8260303pubmed:issue4lld:pubmed
pubmed-article:8260303pubmed:dateCreated1994-1-24lld:pubmed
pubmed-article:8260303pubmed:abstractTextWe have examined the ability of lemakalim to correct bupivacaine-induced cardiac electrophysiological impairment in an experimental electrophysiological model in closed-chest dogs. Two groups (n = 6) of pentobarbitone-anaesthetized dogs were given atropine 0.2 mg kg-1 i.v., and bupivacine 4 mg kg-1 i.v. over 10 s. Group 2 received also lemakalim 0.03 mg kg-1 i.v. Bupivacaine induced bradycardia, prolonged PR and His-ventricle (HV) intervals, QRS duration, QTc and JTc intervals, decreased left ventricular (LV) dP/dt max and increased LV end-diastolic pressure. Lemakalim reversed bupivacaine-induced PR, HV, QRS, QTc and JTc prolongation, and did not worsen bupivacaine-induced bradycardia and haemodynamic depression. We conclude that lemakalim can antagonize the main deleterious electrophysiological effects induced by a large dose of bupivacaine in anaesthetized dogs.lld:pubmed
pubmed-article:8260303pubmed:languageenglld:pubmed
pubmed-article:8260303pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8260303pubmed:citationSubsetIMlld:pubmed
pubmed-article:8260303pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8260303pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8260303pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8260303pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8260303pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8260303pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8260303pubmed:statusMEDLINElld:pubmed
pubmed-article:8260303pubmed:monthOctlld:pubmed
pubmed-article:8260303pubmed:issn0007-0912lld:pubmed
pubmed-article:8260303pubmed:authorpubmed-author:SassineAAlld:pubmed
pubmed-article:8260303pubmed:authorpubmed-author:DeschGGlld:pubmed
pubmed-article:8260303pubmed:authorpubmed-author:GagnolJ PJPlld:pubmed
pubmed-article:8260303pubmed:authorpubmed-author:EledjamJ JJJlld:pubmed
pubmed-article:8260303pubmed:authorpubmed-author:de La...lld:pubmed
pubmed-article:8260303pubmed:authorpubmed-author:LefrantJ YJYlld:pubmed
pubmed-article:8260303pubmed:authorpubmed-author:BassoulBBlld:pubmed
pubmed-article:8260303pubmed:authorpubmed-author:BruellePPlld:pubmed
pubmed-article:8260303pubmed:authorpubmed-author:PerayPPlld:pubmed
pubmed-article:8260303pubmed:issnTypePrintlld:pubmed
pubmed-article:8260303pubmed:volume71lld:pubmed
pubmed-article:8260303pubmed:ownerNLMlld:pubmed
pubmed-article:8260303pubmed:authorsCompleteYlld:pubmed
pubmed-article:8260303pubmed:pagination534-9lld:pubmed
pubmed-article:8260303pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:8260303pubmed:meshHeadingpubmed-meshheading:8260303-...lld:pubmed
pubmed-article:8260303pubmed:meshHeadingpubmed-meshheading:8260303-...lld:pubmed
pubmed-article:8260303pubmed:meshHeadingpubmed-meshheading:8260303-...lld:pubmed
pubmed-article:8260303pubmed:meshHeadingpubmed-meshheading:8260303-...lld:pubmed
pubmed-article:8260303pubmed:meshHeadingpubmed-meshheading:8260303-...lld:pubmed
pubmed-article:8260303pubmed:meshHeadingpubmed-meshheading:8260303-...lld:pubmed
pubmed-article:8260303pubmed:meshHeadingpubmed-meshheading:8260303-...lld:pubmed
pubmed-article:8260303pubmed:meshHeadingpubmed-meshheading:8260303-...lld:pubmed
pubmed-article:8260303pubmed:meshHeadingpubmed-meshheading:8260303-...lld:pubmed
pubmed-article:8260303pubmed:meshHeadingpubmed-meshheading:8260303-...lld:pubmed
pubmed-article:8260303pubmed:meshHeadingpubmed-meshheading:8260303-...lld:pubmed
pubmed-article:8260303pubmed:meshHeadingpubmed-meshheading:8260303-...lld:pubmed
pubmed-article:8260303pubmed:meshHeadingpubmed-meshheading:8260303-...lld:pubmed
pubmed-article:8260303pubmed:meshHeadingpubmed-meshheading:8260303-...lld:pubmed
pubmed-article:8260303pubmed:meshHeadingpubmed-meshheading:8260303-...lld:pubmed
pubmed-article:8260303pubmed:year1993lld:pubmed
pubmed-article:8260303pubmed:articleTitleLemakalim, a potassium channel agonist, reverses electrophysiological impairments induced by a large dose of bupivacaine in anaesthetized dogs.lld:pubmed
pubmed-article:8260303pubmed:affiliationDepartment of Anaesthesia and Intensive Care, University Hospital of Nîmes, France.lld:pubmed
pubmed-article:8260303pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8260303pubmed:publicationTypeComparative Studylld:pubmed